Abstract
Background
To eliminate trachoma as a public health problem, countries must achieve a district-level prevalence of trachomatous inflammation—follicular (TF) <5% in children ages 1–9 years. Re-emergence of TF could trigger additional rounds of mass drug/antibiotic administration (MDA), so accurate tools for use in surveys assessing trachoma prevalence are essential.
Methodology & principal findings
We surveyed 2401 children ages 1–9 years from 50 villages in Kongwa, Tanzania, 2 years post-MDA and 1.5 years after an impact survey found TF <5% in the same villages. Our survey included multiple tools: clinical determination of TF, Cepheid testing for Chlamydia trachomatis infection, and testing for anti-pgp3 antibodies via multiplex bead array. Photographs of the upper tarsal conjunctiva were taken in a subset of children to corroborate the field grades.
Overall TF prevalence in 1–9 year olds was 7.1% (95% CI: 5.6%-8.9%), which decreased with age (p = <0.0001). TF prevalence by village was heterogeneous, with 19 villages having TF <5% and 16 villages having TF >10%. There was a strong correlation between field and photo grading of TF (kappa = 0.69; 95% CI: 0.60–0.78) and between TF and infection, with 21.5% of TF-positive children also testing positive for infection, as compared to only 1.6% of TF-negative children (p = 0.0010). Overall seroprevalence was 18.2% (95% CI: 14.8%-22.1%), which increased with age (p = <0.0001). Notably, 1–2 year olds, who were born after the cessation of MDA and theoretically should not have had exposure to C. trachomatis in the absence of transmission, had an average seroprevalence of 6.7%.
Conclusions & significance
Field TF prevalence, supported by photographic review and infection data, suggested re-emergence of trachoma in Kongwa. Moreover, seropositivity in the children born after cessation of MDA indicated exposure to C. trachomatis despite a previous survey finding of TF <5%. Examining seropositivity in specific age groups expected to have limited exposure to C. trachomatis can be used to detect re-emergence.
Funder
International Trachoma Initiative
El-Maghraby Chair at Wilmer Eye Institute
National Eye Institute
Publisher
Public Library of Science (PLoS)
Subject
Infectious Diseases,Public Health, Environmental and Occupational Health
Reference22 articles.
1. Trachoma. 2020 Aug 11 [cited 1 November 2020]. In: World Health Organization Fact Sheets [Internet]. Geneva: WHO 2020. Available from: https://www.who.int/news-room/fact-sheets/detail/trachoma.
2. World Health Organization. Validation of elimination of trachoma as a public health problem. World Health Organization. 2016. Document number: WHO/HTM/NTD/2016.8. Available from: https://apps.who.int/iris/handle/10665/208901.
3. World Health Organization. Report of the 4th global scientific meeting on trachoma: Geneva, 27–29 November 2018. World Health Organization. 2019. Document number: WHO/CDS/NTD/PCT/2019.03. Available from: https://apps.who.int/iris/handle/10665/325121.
4. Serology for trachoma surveillance after cessation of mass drug administration;DL Martin;PLoS Negl Trop Dis,2015
5. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia.;EM Harding-Esch;PLoS Negl Trop Dis,2013
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献